摘要
目的 探析在新生儿重症感染性肺炎患儿中人免疫球蛋白与红霉素联合治疗的临床疗效及对炎性标志物的作用。方法 选取2022年1月至2024年1月本院收治的60例新生儿重症感染性肺炎患儿，根据随机抽样法将其分组，对照组（30例）采取红霉素治疗，治疗组（30例）在对照组基础上加用人免疫球蛋白治疗。对比两组治疗前后的炎性标志物水平（IL-6、PCT、WBC、CRP），并比较两组治疗后的临床疗效，和治疗期间两组新生儿出现的不良反应情况。结果 两组治疗后的炎性标志物均有明显降低，且治疗组的IL-6、PCT、WBC、CRP水平分别低于对照组，治疗组的临床疗效率高于对照组（P＜0.05）；两组治疗期间的不良反应发生率相比无统计学意义（P＞0.05）。结论 在新生儿重症感染性肺炎患儿中联合应用人免疫球蛋白和红霉素进行治疗，能够显著提高治疗效果，降低患儿的炎症水平，且用药安全性有保障。
关键词： 新生儿；重症；感染性肺炎；人免疫球蛋白；红霉素
Abstract
Objective To explore the clinical efficacy of human immunoglobulin combined with erythromycin in the treatment of neonatal severe infectious pneumonia and its effect on inflammatory markers. Methods 60 cases of neonatal severe infectious pneumonia in our hospital from March 2022 to March 2023 were selected and divided into two groups according to random sampling method. The control group (30 cases) was treated with erythromycin, and the treatment group (30 cases) was treated with human immunoglobulin on the basis of the control group. The levels of inflammatory markers (IL-6 PCT、WBC、CRP), The clinical efficacy of the two groups after treatment and the adverse reactions of newborns in the two groups during treatment were compared. Results the inflammatory markers in the two groups were significantly reduced after treatment, and the levels of IL-6, PCT, WBC, CRP in the treatment group were lower than those in the control group, and the clinical efficiency of the treatment group was higher than that of the control group (P < 0.05); There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P > 0.05). Conclusion the combined application of human immunoglobulin and erythromycin in the treatment of neonatal severe infectious pneumonia can significantly improve the therapeutic effect, reduce the inflammatory level of children, and ensure the safety of medication.
Key words： Newborn; Severe; Infectious pneumonia; Human immunoglobulin; Erythromycin
参考文献 References
[1] 肖敏.人免疫球蛋白联合头孢哌酮钠舒巴坦钠治疗新生儿感染性肺炎的效果分析[J].中国社区医师,2024,39(33):29-31.
[2] 高迪,陈晓敏,马蕊.人免疫球蛋白联合乙酰半胱氨酸对新生儿肺炎患儿临床症状及机体氧化应激水平的影响[J].药品评价,2024,21(04):489-492.
[3] Sha C ,ChunHui Z ,FangGen C , et al.[Establishment of a risk model for severe adenovirus pneumonia and prospective study of the timing of intravenous immunoglobulin therapy in children].[J].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,2023,25(6):619-625.
[4] 樊婷,张云玲.静脉滴注盐酸氨溴索联合红霉素对新生儿重症肺炎的疗效研究[J].长春中医药大学学报,2020, 36(06):1252-1254.
[5] 曹孟宸,张晓媛,赵艳.人免疫球蛋白联合头孢他啶治疗新生儿感染性肺炎的效果观察[J].山东医学高等专科学校学报,2024,46(01):23-24.
[6] 李微,廖惠映,李妹清,等.人免疫球蛋白联合红霉素治疗新生儿感染性肺炎的临床疗效及对炎性标志物的影响分析[J].中国实用医药,2022,17(11):121-123.
[7] 杨国语,周慧珍,刘梦莹.静脉注射不同剂量免疫球蛋白对新生儿肺炎的疗效及其免疫抑制作用[J].临床研究,2022, 30(09):39-42.
[8] Noha A ,Layan A ,Rawan A , et al.Efficacy of erythromycin compared to clarithromycin and azithromycin in adults or adolescents with community-acquired pneumonia: A Systematic Review and meta-analysis of randomized controlled trials.[J].Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022,28(8):1148-1152.
[9] 刘小凰.静注人免疫球蛋白联合布地奈德治疗新生儿肺炎的效果及对肺功能、血清CRP、IL-6、IL-10水平的影响[J].临床合理用药杂志,2022,15(20):132-134.
[10] 周宏侠.阿莫西林克拉维酸钾联合红霉素治疗晚期新生儿感染性肺炎的临床效果[J].中国实用医药,2022,17(13):85-87.